CD274 and esophageal squamous cell carcinoma: For ESCC patients without PD-L1 expression (HR = 0.62, 95% CI: 0.57-0.67), those with PD-L1 expression ≥1% (HR = 0.57, 95% CI: 0.51-0.63), and those with PD-L1 expression ≥10% (HR = 0.53, 95% CI: 0.47-0.60), the combination therapy yielded significant PFS benefits.